LC, yes imo there is a reason. In one of dr. Liau's presentations from 2023 or 2024 she talks about submitting for approval using external controls w/o patient level matched data that the UK EU and I think she also included Canada are more open to use of such controls than the fda. Also location of the manufacturer in uk